Safety and Efficacy of Bidirectional(Intraperitoneal and systemic) chemotherapy for advanced gastric cancer patients with peritoneal metastasis
- Conditions
- Neoplasms
- Registration Number
- KCT0003187
- Lead Sponsor
- Seoul National University Bundang Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 43
Adenocarcinoma of stomach by endoscopic biopsy, primary or recurrent
- Peritoneal carcinomatosis proved with CT or diagnostic laparoscopy
- Decided to use mFOLFOX-6 treatment in Multi-Disciplinary outpatient clinic
- No previous chemotherapy for gastric cancer, or 4 weeks after previous chemotherapy
- Adequate blood exam ( Within 2 weeks of treatment)
?Neutrophil ? 1,500/mm3??
?Hb ? 8.0g/dL
?Platelet? 10×104/mm3
?GOT /GPT ? 100U/L
?Total bilirubin? 2.0mg/dL
?Creatinine Clearance(CCl)? 50mL/min
- Performance status 0-2
- Her-2 negative
- Age between 20 to 80 years old
- Accompanying severe medical disease or other malignancies
- Contraindication of using Fluorouracil, Oxaliplatin, Leucovorin or Paclitaxel
- Pregnant or currently breast feeding or possibility of pregnancy
- Rejection of treatment
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Recommended dose of Paclitaxel;1 year overall survival
- Secondary Outcome Measures
Name Time Method Side effects rate;1 year progression free survival;Target lesion response evaluation;Peritoneal seeding response evaluation;Conversion surgery